Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
693.50
-1.49 (-0.21%)
At close: Nov 14, 2025, 4:00 PM EST
691.50
-2.00 (-0.29%)
After-hours: Nov 14, 2025, 7:56 PM EST
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.75B in the quarter ending September 30, 2025, with 0.90% growth. This brings the company's revenue in the last twelve months to $14.25B, up 2.89% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.25B
Revenue Growth
+2.89%
P/S Ratio
5.15
Revenue / Employee
$943,188
Employees
15,106
Market Cap
71.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
REGN News
- 3 days ago - Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs - GlobeNewsWire
- 5 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript - Seeking Alpha
- 9 days ago - Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review - GlobeNewsWire
- 12 days ago - Regeneron Announces Investor Conference Presentations - GlobeNewsWire
- 16 days ago - Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award - GlobeNewsWire
- 17 days ago - Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback - Seeking Alpha
- 17 days ago - Market Starting To Embrace The 'New' Regeneron - Seeking Alpha
- 18 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript - Seeking Alpha